| c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines BB Brasher, RA Van Etten Journal of Biological Chemistry 275 (45), 35631-35637, 2000 | 359 | 2000 |
| Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop S Roumiantsev, NP Shah, ME Gorre, J Nicoll, BB Brasher, CL Sawyers, ... Proceedings of the National Academy of Sciences 99 (16), 10700-10705, 2002 | 331 | 2002 |
| USP7 small-molecule inhibitors interfere with ubiquitin binding L Kategaya, P Di Lello, L Rougé, R Pastor, KR Clark, J Drummond, ... Nature 550 (7677), 534-538, 2017 | 287 | 2017 |
| Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling S Li, AD Couvillon, BB Brasher, RA Van Etten The EMBO journal 20 (23), 6793-6804, 2001 | 126 | 2001 |
| K63-linked polyubiquitin chains bind to DNA to facilitate DNA damage repair P Liu, W Gan, S Su, AV Hauenstein, T Fu, B Brasher, C Schwerdtfeger, ... Science signaling 11 (533), eaar8133, 2018 | 100 | 2018 |
| Reactive-site-centric chemoproteomics identifies a distinct class of deubiquitinase enzymes DS Hewings, J Heideker, TP Ma, AP AhYoung, F El Oualid, A Amore, ... Nature Communications 9 (1), 1162, 2018 | 90 | 2018 |
| Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain BB Brasher, S Roumiantsev, RA Van Etten Oncogene 20 (53), 7744-7752, 2001 | 73 | 2001 |
| Combination pharmaceutical agents as inhibitors of HCV replication YS Or, CM Owens, BB Brasher, YL Qiu, L Jiang US Patent 9,060,971, 2015 | 63 | 2015 |
| Structural and functional characterization of ubiquitin variant inhibitors of USP15 J Teyra, AU Singer, FW Schmitges, P Jaynes, SKL Lui, MJ Polyak, N Fodil, ... Structure 27 (4), 590-605. e5, 2019 | 52 | 2019 |
| DUB-resistant ubiquitin to survey ubiquitination switches in mammalian cells M Békés, K Okamoto, SB Crist, MJ Jones, JR Chapman, BB Brasher, ... Cell reports 5 (3), 826-838, 2013 | 44 | 2013 |
| Targeting of proteins to membranes through hedgehog auto-processing S Vincent, A Thomas, B Brasher, JD Benson Nature biotechnology 21 (8), 936-940, 2003 | 41 | 2003 |
| Methods for identifying peptide aptamers capable of altering a cell phenotype J Benson, S Vincent, B Brasher US Patent App. 10/263,577, 2003 | 16 | 2003 |
| Proteomics of broad deubiquitylase inhibition unmasks redundant enzyme function to reveal substrates and assess enzyme specificity V Rossio, JA Paulo, J Chick, B Brasher, SP Gygi, RW King Cell chemical biology 28 (4), 487-502. e5, 2021 | 14 | 2021 |
| Yeast two-hybrid analysis for ubiquitin variant inhibitors of human deubiquitinases N Pascoe, A Seetharaman, J Teyra, N Manczyk, MA Satori, D Tjandra, ... Journal of molecular biology 431 (6), 1160-1171, 2019 | 8 | 2019 |
| Preclinical and clinical resistance profile of EDP-239, a novel hepatitis C virus NS5A inhibitor CM Owens, BB Brasher, A Polemeropoulos, MHJ Rhodin, N McAllister, ... Antimicrobial agents and chemotherapy 60 (10), 6216-6226, 2016 | 5 | 2016 |
| Preclinical profile and clinical efficacy of a novel hepatitis C virus NS5A inhibitor, EDP-239 CM Owens, BB Brasher, A Polemeropoulos, MHJ Rhodin, N McAllister, ... Antimicrobial agents and chemotherapy 60 (10), 6207-6215, 2016 | 4 | 2016 |
| 1213 A HIGHLY POTENT HCV NS5A INHIBITOR EDP-239 WITH FAVORABLE PRECLINICAL PHARMACOKINETICS LJ Jiang, S Liu, T Phan, C Owens, B Brasher, A Polemeropoulos, X Luo, ... Journal of hepatology, S479, 2011 | 4 | 2011 |
| Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype J Benson, S Vincent, B Brasher, Z Miao, D Lamming US Patent App. 10/833,951, 2005 | 4 | 2005 |
| 8 POTENT HCV PROTEASE INHIBITORS WITH THE POTENTIAL FOR ONCE-DAILY DOSING AND BROAD GENOTYPE COVERAGE LJ Jiang, Y Gai, T Middleton, K Kurtz, L Lu, S Liu, T Phan, X Luo, T Poon, ... Journal of Hepatology, S6, 2009 | 3 | 2009 |
| A point mutation in the ABL catalytic domain induces resistance to the tyrosine kinase inhibitor STI 571. S Roumiantsev, BB Brasher, RA Van Etten Blood 96 (11), 470A-470A, 2000 | 3 | 2000 |
Richard A. Van EttenProfessor of Medicine, University of California, Irvine在 uci.edu 的电子邮件经过验证
